These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30932365)

  • 1. Staging of nutrition disorders in non-small-cell lung cancer patients: utility of skeletal muscle mass assessment.
    Antoun S; Morel H; Souquet PJ; Surmont V; Planchard D; Bonnetain F; Foucher P; Egenod T; Krakowski I; Gaudin H; Debieuvre D
    J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):782-793. PubMed ID: 30932365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study.
    Atlan P; Bayar MA; Lanoy E; Besse B; Planchard D; Ramon J; Raynard B; Antoun S
    Support Care Cancer; 2017 Nov; 25(11):3365-3373. PubMed ID: 28593463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value.
    Srdic D; Plestina S; Sverko-Peternac A; Nikolac N; Simundic AM; Samarzija M
    Support Care Cancer; 2016 Nov; 24(11):4495-502. PubMed ID: 27236439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What's next in using CT scans to better understand cachexia?
    Antoun S; Rossoni C; Lanoy E
    Curr Opin Support Palliat Care; 2018 Dec; 12(4):427-433. PubMed ID: 30239385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer.
    Sjøblom B; Grønberg BH; Wentzel-Larsen T; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Bye A; Jordhøy M
    Clin Nutr; 2016 Dec; 35(6):1386-1393. PubMed ID: 27102408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT).
    Recio-Boiles A; Galeas JN; Goldwasser B; Sanchez K; Man LMW; Gentzler RD; Gildersleeve J; Hollen PJ; Gralla RJ
    Support Care Cancer; 2018 Jul; 26(7):2353-2359. PubMed ID: 29417293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscle mass and association to quality of life in non-small cell lung cancer patients.
    Bye A; Sjøblom B; Wentzel-Larsen T; Grønberg BH; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Jordhøy M
    J Cachexia Sarcopenia Muscle; 2017 Oct; 8(5):759-767. PubMed ID: 28493418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive validation of the functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia subscale (A/CS) in lung cancer patients with involuntary weight loss.
    Gelhorn HL; Gries KS; Speck RM; Duus EM; Bourne RK; Aggarwal D; Cella D
    Qual Life Res; 2019 Jun; 28(6):1641-1653. PubMed ID: 30796591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study.
    Takayama K; Atagi S; Imamura F; Tanaka H; Minato K; Harada T; Katakami N; Yokoyama T; Yoshimori K; Takiguchi Y; Hataji O; Takeda Y; Aoe K; Kim YH; Yokota S; Tabeta H; Tomii K; Ohashi Y; Eguchi K; Watanabe K
    Support Care Cancer; 2016 Aug; 24(8):3473-80. PubMed ID: 27003901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system.
    Op den Kamp CM; Langen RC; Minnaard R; Kelders MC; Snepvangers FJ; Hesselink MK; Dingemans AC; Schols AM
    Lung Cancer; 2012 Apr; 76(1):112-7. PubMed ID: 22018880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer.
    Suzuki Y; Okamoto T; Fujishita T; Katsura M; Akamine T; Takamori S; Morodomi Y; Tagawa T; Shoji F; Maehara Y
    Lung Cancer; 2016 Nov; 101():92-97. PubMed ID: 27794415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarcopenic obesity by the ESPEN/EASO criteria for predicting mortality in advanced non-small cell lung cancer.
    Zhou J; Luo L; Xie L; Hu S; Tan L; Lei X; Luo X; Yang M
    Clin Nutr; 2023 Jun; 42(6):817-824. PubMed ID: 37084468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non-small cell lung cancer.
    Kakinuma K; Tsuruoka H; Morikawa K; Furuya N; Inoue T; Miyazawa T; Mineshita M
    Thorac Cancer; 2018 Jan; 9(1):99-104. PubMed ID: 29067769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer.
    LeBlanc TW; Nipp RD; Rushing CN; Samsa GP; Locke SC; Kamal AH; Cella DF; Abernethy AP
    J Pain Symptom Manage; 2015 Apr; 49(4):680-9. PubMed ID: 25461669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS).
    LeBlanc TW; Samsa GP; Wolf SP; Locke SC; Cella DF; Abernethy AP
    Support Care Cancer; 2015 Aug; 23(8):2341-7. PubMed ID: 25586527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of low skeletal muscle mass on non-lung cancer mortality after stereotactic body radiotherapy for patients with stage I non-small cell lung cancer.
    Matsuo Y; Mitsuyoshi T; Shintani T; Iizuka Y; Mizowaki T
    J Geriatr Oncol; 2018 Nov; 9(6):589-593. PubMed ID: 29779799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary report.
    Cortellini A; Verna L; Porzio G; Bozzetti F; Palumbo P; Masciocchi C; Cannita K; Parisi A; Brocco D; Tinari N; Ficorella C
    Thorac Cancer; 2019 Feb; 10(2):347-351. PubMed ID: 30600905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consequences of Late-Stage Non-Small-Cell Lung Cancer Cachexia on Muscle Metabolic Processes.
    Murton AJ; Maddocks M; Stephens FB; Marimuthu K; England R; Wilcock A
    Clin Lung Cancer; 2017 Jan; 18(1):e1-e11. PubMed ID: 27461772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship Between Preoperative Sarcopenia Status and Immuno-nutritional Parameters in Patients with Early-stage Non-small Cell Lung Cancer.
    Shoji F; Matsubara T; Kozuma Y; Haratake N; Akamine T; Takamori S; Katsura M; Toyokawa G; Okamoto T; Maehara Y
    Anticancer Res; 2017 Dec; 37(12):6997-7003. PubMed ID: 29187486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of sarcopenia and observed physical performance with attainment of multidisciplinary team planned treatment in non-small cell lung cancer: an observational study protocol.
    Collins JT; Noble S; Chester J; Davies HE; Evans WD; Lester J; Parry D; Pettit RJ; Byrne A
    BMC Cancer; 2015 Jul; 15():544. PubMed ID: 26204885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.